Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LEXX has NOT announced that Premier has made a payment to maintain exclusivity. Those payments were set to start September 1st. Given how often LEXX throws out pressers, I figure this payment was not made.
1) They aren't a "big name player"
2) LEXX is 0.1% of their portfolio
3) They own more than 200 stocks and its a mutual fund strategy
I mean, as much as I agree with you, this has been the status quo at this company the entire time. To say they will "eventually" want answers is such an understatement. The issue is that there is absolutely no way to hold anyone accountable here. It won't change. The onus here is on the investors, they should be aware of the structure and invest at their own risk. The company is an absolute joke
Altria put a little money in, kept an eye on it, and ended up passing. Doubtful that any large tobacco company comes in for another deal anytime soon.
The company is just an annuity for him
Ha, this deal is a joke.
payments could be very significant, but the chances they happen are small. Have you heard a single word about them yet?
Also, the payments are for exclusivity. In order for them to want to pay that much for exclusivity, they would have to see LEXX coming close to making valuable deals with competitors (which they aren't,) AND would have to be generating a ALOT of revenue and profits from their products made with DehydraTECH, which they AREN'T.
Also, payments start September 1, 2022, we are well past that date and haven't heard a word. This was another nonsense deal and announcement.
Jazz doesn't need Dehydratech.
I didn't mean Jazz could run a trial with Dehydratech. I meant that Jazz could easily run trials for additional uses for an already approved drug, Epiliodex and get it approved pretty quickly, years before LEXX. One of these could be hypertension.
As said before, CBD is the important component to the drug, NOT dehydratech, which is the delivery platform. Yes I agree dehydratech makes it more bioavailable, but CBD is cheap enough to produce with almost no side effects, so lowering the amount needed isn't extremely helpful
I'm not cruising, I keep tabs as someone who has traded in the stock and used to hold it as well.
That being said, you're sarcasm is pretty hilarious considering anyone holding this stock HAS been losing the majority of what's been invested in it
Read this it's good advice and insight I promise
Some folks here, you know who they are, do not have your best interest at heart, they are likely buying and selling on small pumps. The more you dig into this company the more it looks bad. There's a reason they've never produced any value.
In my younger years I made some good money on this company, knowing full well it was likely trash but it was a good trade when weed what the hottest thing in the markets. I held a bit longer and lost a bit of it. I keep an eye on LEXX, mostly just to see if there are small trades to be made to make some quick money, because when it moves, it moves a lot.
Long-term, this is absolutely not a buy and hold company, its ALWAYS comes back down. I am a professional investor primarily in biopharma. I have traded this stock here and there on the side. I made a lot of money of GWPH as they were developing Epiliodex.
There is a right way and a wrong way to develop drugs, and these little side studies by LEXX are barely even "proof of concept" and the concept they are proving has already been proved. To get FDA approval for something that already exists it needs to exhibit a clear difference and benefit to the patient. Dehydratech is a great technology if it does that they say, and could be very useful, but it's not good enough for LEXX to do anything other than maybe license it to others.
Every company in this space is very aware of what everyone else is doing, so it's safe to say that any potential partners, if they've even been spoken to, don't see a tremendous benefits to LEXX's delivery platform. Altria, for example, put a paltry amount of money as a call option into LEXX, then decided it wasn't even worth pocket change to put more in.
Those thinking Altria missed out...you don't know more than them. The best advice I can give you is to sell this PoS, it's barely a viable company with nothing developed and almost no progress and no money.
Now here is a very important part if they want to advance any trials AT ALL.
- The company has $7mm of cash, they would need A LOT more to even get data that a larger pharma would care about. The market cap is $12mm...so if they even want to raise $10mm, they would dilute shareholders by almost 50%...That's the main problem with tiny biotech companies....raising ANY cash is insanely dilutive.
I am not a "basher," which is what pumpers refer to someone who says negative things about a company. I am not short this stock, I'd love for it to succeed and I'll keep checking in here and there. I know a lot of folks here are just saying positive things to get new people and others to keep the faith in this company, but if you are a small retail investor hoping for a lifechanging stock win, I can almost guarantee you, the best return in the foreseeable future with this stock, will be the tax savings that will come from selling. Keep an eye out, they will raise more money and the stock will not go up in a significant way until that happens.
They declared their hypertension study a success. They would still be a very long way away from having this be an approved drug with the FDA.
Jazz, which owns Epiliodex, could run an identical trial at scale, with epiliodex for an additional indication in a heartbeat and just add that to the list of things epiliodex can be prescribed for. Because as discussed. CBD is the main thing here, not Dehydratech. Sure they can use smaller doses with LEXX, BUT CBD is pretty non-toxic and very cheap, so smaller doses doesn't help much
They have enerv even come close to finding a partner on anything they've done, for a reason. I don't think they have the goods and I think the company is an annuity for Bunka that he knows will never do much.
Also, CBD, which is what epiliodex, doesn't harm the liver, CBD in fact is helpful if anything. So there is no need to "protect the liver" from something like epiliodex.
Also, other potential brain benefits doesn't help sell a drug that is largely identical to another of the size of epiliodex if that's not specifically proven in a large study over time. Anecdotes like that are irrelevant.
I didn't miss it, I just see how long its taken and how it's unlikely to be a big drug in this space to be honest. I keep tabs on the stock as I sold a while back but keep trying to decide if I want to get back in.
Last time I wrote a long bit on the shortcomings of the hyper study was summer 2021 I think, stock down 60% or so since then.
Tax sales
Everyone here, or almost everyone, I have to assume has a losing position on this stock. I don't believe it will go anywhere but some pump and dumps for the company to issue more equity.
Certainly nothing big happening in the next 30 days.
You should all sell for the tax loss and then re-assess whether or not to buy back in 31 days later. I bet most of you will decide that there is a better use for that cash than this stock and it will free you from this constant waiting and slow death of its value.
The tobacco study doesn't matter much, ON! and Zyn have the market outside of the traditional dips and side effects aren't bad enough for people to care about dehydratech,
The epilepsy study is also fairly hopeless. Epiliodex is already on pace to be a $1bn drug in the next couple of years and the amount of money it would take to crack that market and take share is far more than LEXX will ever have. Commercialization is insanely expensive. They also would have to be significantly better in order to win approval or show much better in the side effects department. I don't think that one has legs. Their tech has more to do with absorption speeds than anything else and epiliodex is a daily medicine not an as needed medicine, so speed isn't important.
Cash and Burn:
They are raising cash since August 12 it seems, planning to sell shares worth about 1/3 of current mkt cap, which is insane (announcing 2 days after releasing a bullsh*t article where the FDA basically just said "okay we agree you should test this on 100 people."
They will continue to burn cash, then whenever they release something like this, they will raise again and dilute shortly after.
This is a nonsense study. They talk about how big the dimentia market is...All they are doing is running a test that nicotine and CBD helps symptoms of dimentia such as agitaiton and anxiety, not actually the causes and primary symptoms of dimentia.
Week before split stock was over $8 equivalent, the day before the split was announced it was $7.55...we are nowhere near "pre-split levels." Year before the split was at $14.
In fact, if you'd bought the day after the split caused the stock to crash briefly, you'd still be down.
The stock is only above all time lows that it hit in May
That's a projection based on projected sales for a product that doesn't exist yet.
The actual deal for exclusivity would yield $5mm total IF they get paid it.
You made it seem like it's reasonable to expect $5mm per year, which it's not at all.
NOT $5mm per year
"In order to retain ongoing exclusivity, the negotiated minimum quarterly payments ("Payments") to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to US$4,527,500."
It DOES NOT say this amount PER YEAR...if it was per year, it would be explicit. That's the total. Also, that is only to maintain EXCLUSIVITY. They do not need to maintain exclusivity at the moment as Lexaria has no other Japan deals ad hasn't mentioned any. So, it's feasable that they never make any of these payments unless a major competitor wants to use the tech.
Also, who cares what this company's PARENT sales are. This is a red herring to make people think this deal has large potential. At the moment, this company's revenue do not come from products that LEXX's tech will help, so they are creating new products (maybe).
The article doesn't even mention what products might be created.
This partnership at the moment, is fairly meaningless and basically says nothing more than "Japanese cosmetics company might start using our technology, and if they do, we will get royalty payments, but we aren't saying what they are. BUT, they would have to pay to keep us from licensing our tech to other Japanse companies, but we haven't started doing that yet either."
Yes this is a nothing announcement and shows how full of crap these folks are
Becaue they aren't actually important or particularly good and the management has proven a disaster for years. You see this constantly. People care about management and capital management and this company is terrible at that and hasn't produced anything. The data they release from time to time isn't actually that good (if it was, others would take notice).
The way this stock trades is some folks buy on a hot tip after a paid article comes out, then they jump a bit and sell, and it just goes down as people give up before the next pump.
It's not that thigs aren't adding up, it's that nothing good will happen with the share price until they start making money. It's been too long so people gave up on buying before anything happens
Potential outcomes, expectations
There are 5mm outstanding shares and 200mm authorized!! Basically, the company can conitnue to just issue shares and dilute everyone (no reason to expect they would ever stop doing this as it's ALL they have really done over the ast few years).
If you invested around the Altria deal, you'd be down 90% and would need a 10x from here to break even...what are the chances you think that could EVER happen with this many shares authorized?
Hate to be a downer here, but there's not much reason to invest in this pile as long as Bunka is in charge...constant promises with nothing to show other than mostly useless new patents that he just uses to pretend he's making progress.
Japanese deal not that great
"In order to retain ongoing exclusivity, the negotiated minimum quarterly payments ("Payments") to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to US$4,527,500"
this is less than $1mm per year and it's only if the company want to retain exclusivity. Given Lexaria has no other potential deals on the horizon, they don't need to maintain exclusivity. So, in short, even if they make these payments, it doens't mean much for the company, and they aren't that likely to anyway.
That's the worst reasoning I've ever heard.
He's the biggest shareholder because he pays himself in shares every year despite no performance.
That argument may hold up if he EVER spent money on shares (I don't count the recent $30k).
If this company was actually going somewhere, he would be putting his money where his mouth is. Instead, he pumps the stock, and then raises money to pay himself and the other guys...
I don't think their tech would do that much for Epidiolex. For starters, CBD is pretty inexpensive and they don't really need to up its bioavailability for these indications, they only use around 20-25mg a day in a liquid. At best, Epidiolex would benefit from the change in flavor and not having to use strawberry flavoring.
GWPH is unlikely to need dehydratech to improve their product.
LEXX won't go through the FDA on it's own because it would need a long time and a LOT of money to do trials for something like this. GWPH used hundreds of patients for 3.5 months at a time to test theirs
I know plenty of companies that have CBD oil extrtacted into clear liquids with no suspended solids. There really isn't anything particularly special with it
Epiliodex does NOT have a special delivery mechanism. It's purified CBD with alcohol (tincture) and sugar and flavoring so it's appealing to kids.
You've posted back to back posts with highly misleading information in a row
Its required to put literally any potential side effect on the list. Almost every prescription I've seen lists diarrhea and other upset stomach issues as a potential side effect. Many other medicines list elevated liver enzymes as side effects too. Tylenol lists this, not a big deal.
As for the 90% you reference...be careful with how you present data.
The REAL quote
Furthermore, it's notable that nearly 90% of patients in Dr. Leehey's study had diarrhea; whereas, this wasn't reported in other Epidiolex studies, which suggests either PD patients have a negative GI response to Epidiolex, or there are potential inconsistencies in the formulations being tested
Diarrhea occurred in 18.6% of patients treated for seizures. Other studies have found that of people suffering from epilepsy, 25% who took the placebo had diarrhea and just 31% of treated patients, showing that it's really not a big deal
How long and how much money do you think it will take for LEXX to get this approved?
This company has been run poorly for years as the management takes out money and dilutes shareholders and BARELY EVEN SPENDS MONEY ON DEVELOPING ANYTHING.
GWPH spent years and millions developing a drug and getting through the FDA.
What you seem to not realize is that a company that spends ANY MONEY marketing their stock like LEXX does, does so just so they can have the price rise, raise money, pay themselves at the cost of investors
FDA Approval Finalized??!! They aren't even in trials!
Few things everyone should be aware of:
1) They will never go through FDA approvals themselves. They would have to dilute everyone by half to get the funds to do this.
2) Best hope is for a licensing deal, which would AT BEST be a one time
payment with royalties.
3) These royalties won't come until THAT company goes through the FDA, multiple years.
4) Dehydratech DOES NOT lower blood pressure. CBD does. LEXX tech helps it work just a little faster. Their study in July showed that it was a bit better after 20 mins, but after 40 mins, it was back to the same. So it helps speed up absorption by a little.
5) NONE OF THIS has been proven in larger independent studies
6) IF this data was truly meaningful...and the studies were independent and larger, then guess what, larger companies that are using CBD for medicines would have pounced on this. There are CBD products being put through the FDA for other conditions, and none of them care about LEXX tech.
Most here pre-split
I believe: This stock has been a wild disappointment.
Massive dilution, false promises. There doesn't appear to be any real effort here from management other than to keep their salaries.
If they had real ambitions for a big product, they wouldn't be spending less on R&D than on salaries, and almost as much on marketing as R&D.
If you have some winnings on this one, get out and forget it exists.
testing just 16 patients in a blood pressure trial that's insanely cheap to do, doesn't really help
absolutely NOTHING is "brewing," except MAYBE another paid article and a quick intraday 10% bump
Tabby - pumper
On another forum here I once said something concerning about a stock and got a private message from someone outlining the strategies we should employ to try and push the stock up. They included randomly posting positive and excited messages like "Lets go xx!!!." It's very sad but something that clearly has happened for a long time with LEXX.
Nothing but angry messages from you at people expressing concern / random pump posts to try and distract from the bad ones.
he absolutely is NOT buying more stock. He gets GIVEN stock that he doesn't care about.
Bunka is feeling NO pain
He has spend like two months salary in entirety on his stock position. Has spent like $30k in the last 10 years on stock. He isn't feeling any pain. He is happy enough to chug along, have his options, get paid in cash, and continue to raise money in order to pay that salary. He's a complete fraud...
His messaging about accumulating data so they can go to larger biotech's is absolute nonsense. Nobody should believe that load of crap. Successful companies publish data, and more importantly, spend MONEY on it... not on legal, marketing and consulting.
Usually I would say okay, but there's nothing to disagree here on...You claim they raise money continuously because they are an R&D company, but less than 20% of the money they raise goes into R&D, it's a small fraction of their salaries.
Most R&D companies don't dilute this much every single year and pay management like this
They aren't an R&D company...
Further to this point, they are spending less than $500k on R&D a year...they just raised $11mm and will raise more than that once the warrants get exercised (if the stock ever gets up there). They gave "guidance" on R&D which don't have much to do with the previous direction of the company, using Covid as a buzzword and providing ABSLUTELEY NO GUIDANCE ON HOW MUCH THEY ACTUALLY PLAN TO SPEND
I am not saying you can't make money on this stock, but long term it's going to keep going down down down.
Sell those 20%+ days and buy back when it gets cut in half, pay attention to the pump tweets
How many shares they were authorized means nothing. Saying "they had authorization to do worse" doesn't mean they held back.
If they were a true R&D company, they would be spending most of that money on R&D, they didn't come close to that. More was spent on management salaries and marketing etc than R&D.
They 100% did not "control it." Many companies have huge authorizaitons, especially when they are insider controlled. That's nonsense.
Limited dilution?
They raised money and diluted CONSTANTLY
Warrants and dilution
Excuse the rounding:
The after the split, the company raised an additional 1.8mm shares and 1.8mm warrants...tha's 37.5% dilution immediately and another 37.5% of warrant dilution in the future.
There are still 1.8mm warrants now. So there's a massive overhang on the stock that will prevent it from reaching that $8 a share again (post-split, pre dilution). This happens all the time, a stock won't get bought up to the warrant price unless it's going to blow past it by a lot because the second those are triggered, the shares are worth so much less.
THis dilution was horrible for shareholders. We'll see how they actually start to spend this new money. If their salaries go up and R&D doesn't increase ten-fold, then we'll know for sure these are scammers.